Live attenuated leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 2138-2149

  Dey, Ranadhir ^a   Dagur, Pradeep K ^b   Selvapandiyan, Angamuthu ^c   McCoy, J Philip ^b   Salotra, Poonam ^d   Duncan, Robert ^a   Nakhasi, Hira L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c Institute of Molecular Medicine   (India)

^d SAFDARJUNG HOSPITAL CAMPUS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; LEISHMANIA VACCINE; LIVE VACCINE; NITRIC OXIDE; PROTEIN P27; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS; LIVER; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PARASITE LOAD; PARASITE VIRULENCE; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; TH1 CELL; TH2 CELL;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, PROTOZOAN; CROSS PROTECTION; ELECTRON TRANSPORT COMPLEX IV; FEMALE; GENE DELETION; IMMUNIZATION; IMMUNOLOGIC MEMORY; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; SPLEEN; T-LYMPHOCYTES; TIME; VACCINES, ATTENUATED;

EID: 84874241353     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202801     Document Type: Article

References (75)

1. Desjeux, P. 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27: 305-318.
2. Desjeux, P. 1992. Human leishmaniases: epidemiology and public health aspects. World Health Stat. Q. 45: 267-275.
3. Murray, H. W., J. D. Berman, C. R. Davies, and N. G. Saravia. 2005. Advances in leishmaniasis. Lancet 366: 1561-1577.
4. Bañuls, A. L., P. Bastien, C. Pomares, J. Arevalo, R. Fisa, and M. Hide. 2011. Clinical pleiomorphism in human leishmaniases, with special mention of asymptomatic infection. Clin. Microbiol. Infect. 17: 1451-1461.
5. Kaye, P. M., and T. Aebischer. 2011. Visceral leishmaniasis: immunology and prospects for a vaccine. Clin. Microbiol. Infect. 17: 1462-1470.
6. Kaye, P., and P. Scott. 2011. Leishmaniasis: complexity at the host-pathogen interface. Nat. Rev. Microbiol. 9: 604-615.
7. Harhay, M. O., P. L. Olliaro, D. L. Costa, and C. H. Costa. 2011. Urban parasitology: visceral leishmaniasis in Brazil. Trends Parasitol. 27: 403-409.
8. Selvapandiyan, A., R. Dey, S. Gannavaram, I. Lakhal-Naouar, R. Duncan, P. Salotra, and H. L. Nakhasi. 2012. Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. J. Trop. Med. 2012: 631460.
9. Bacellar, O., C. Brodskyn, J. Guerreiro, M. Barral-Netto, C. H. Costa, R. L. Coffman,W. D. Johnson, and E. M. Carvalho. 1996. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J. Infect. Dis. 173: 1515-1518.
10. Bacellar, O., A. D'oliveira, Jr., S. Jerônimo, and E. M. Carvalho. 2000. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12: 1228-1231.
11. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, and P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organspecific phases in the control of Leishmania donovani. Eur. J. Immunol. 28: 669-680.
12. Ghalib, H. W., J. A. Whittle, M. Kubin, F. A. Hashim, A. M. el-Hassan, K. H. Grabstein, G. Trinchieri, and S. G. Reed. 1995. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. 154: 4623-4629.
13. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)- associated response model. J. Exp. Med. 185: 867-874.
14. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kaplan, and R. L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70: 6284-6293.
15. Mege, J. L., S. Meghari, A. Honstettre, C. Capo, and D. Raoult. 2006. The two faces of interleukin 10 in human infectious diseases. Lancet Infect. Dis. 6: 557-569.
16. Nylén, S., and D. Sacks. 2007. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 28: 378-384.
17. Cummings, H. E., R. Tuladhar, and A. R. Satoskar. 2010. Cytokines and their STATs in cutaneous and visceral leishmaniasis. J. Biomed. Biotechnol. 2010: 294389.
18. Silvestre, R., A. Cordeiro-da-Silva, and A. Ouaissi. 2008. Live attenuated Leishmania vaccines: a potential strategic alternative. Arch. Immunol. Ther. Exp. (Warsz.) 56: 123-126.
19. Kedzierski, L., Y. Zhu, and E. Handman. 2006. Leishmania vaccines: progress and problems. Parasitology 133(Suppl): S87-S112.
20. Modabber, F. 1995. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89(Suppl 1): 83-88.
21. Haldar, J. P., S. Ghose, K. C. Saha, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 42: 702-707.
22. Kamil, A. A., E. A. Khalil, A. M. Musa, F. Modabber, M. M. Mukhtar, M. E. Ibrahim, E. E. Zijlstra, D. Sacks, P. G. Smith, F. Zicker, and A. M. El- Hassan. 2003. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérin, a candidate vaccine for visceral leishmaniasis: safety, skindelayed type hypersensitivity response and dose finding in healthy volunteers. Trans. R. Soc. Trop. Med. Hyg. 97: 365-368.
23. Zijlstra, E. E., A. M. el-Hassan, A. Ismael, and H. W. Ghalib. 1994. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am. J. Trop. Med. Hyg. 51: 826-836.
24. Lauring, A. S., J. O. Jones, and R. Andino. 2010. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28: 573-579.
25. Svenson, S., G. Källenius, A. Pawlowski, and B. Hamasur. 2010. Towards new tuberculosis vaccines. Hum. Vaccin. 6: 309-317.
26. Larsen, M. H., K. Biermann, B. Chen, T. Hsu, V. K. Sambandamurthy, A. A. Lackner, P. P. Aye, P. Didier, D. Huang, L. Shao, et al. 2009. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27: 4709-4717.
27. Alexander, J., G. H. Coombs, and J. C. Mottram. 1998. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161: 6794-6801.
28. Gorczynski, R. M. 1985. Immunization of susceptible BALB/c mice against Leishmania braziliensis. I. Resistance induced using as immunogen adherent or nonadherent cells from infected mice. Cell. Immunol. 94: 1-10.
29. Daneshvar, H., G. H. Coombs, P. Hagan, and R. S. Phillips. 2003. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J. Infect. Dis. 187: 1662-1668.
30. Kimsey, P. B., C. M. Theodos, T. K. Mitchen, S. J. Turco, and R. G. Titus. 1993. An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infect. Immun. 61: 5205-5213.
31. Mitchell, G. F., E. Handman, and T. W. Spithill. 1984. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust. J. Exp. Biol. Med. Sci. 62: 145-153.
32. Rivier, D., R. Shah, P. Bovay, and J. Mauel. 1993. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol. 15: 75-84.
33. Uzonna, J. E., G. F. Späth, S. M. Beverley, and P. Scott. 2004. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172: 3793-3797.
34. Zhang, W. W., and G. Matlashewski. 2001. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol. Microbiol. 39: 935-948.
35. Silvestre, R., A. Cordeiro-Da-Silva, N. Santarém, B. Vergnes, D. Sereno, and A. Ouaissi. 2007. SIR2-deficient Leishmania infantum induces a defined IFNgamma/ IL-10 pattern that correlates with protection. J. Immunol. 179: 3161-3170.
36. Papadopoulou, B., G. Roy, M. Breton, C. Kündig, C. Dumas, I. Fillion, A. K. Singh, M. Olivier, and M. Ouellette. 2002. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun. 70: 62-68.
37. Selvapandiyan, A., R. Dey, S. Nylen, R. Duncan, D. Sacks, and H. L. Nakhasi. 2009. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J. Immunol. 183: 1813-1820.
38. Dey, R., C. Meneses, P. Salotra, S. Kamhawi, H. L. Nakhasi, and R. Duncan. 2010. Characterization of a Leishmania stage-specific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence. Mol. Microbiol. 77: 399-414.
39. Selvapandiyan, A., R. Duncan, A. Debrabant, S. Bertholet, G. Sreenivas, N. S. Negi, P. Salotra, and H. L. Nakhasi. 2001. Expression of a mutant form of Leishmania donovani centrin reduces the growth of the parasite. J. Biol. Chem. 276: 43253-43261.
40. Debrabant, A., M. B. Joshi, P. F. P. Pimenta, and D. M. Dwyer. 2004. Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int. J. Parasitol. 34: 205-217.
41. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
42. Selvapandiyan, A., R. Duncan, J. Mendez, R. Kumar, P. Salotra, L. J. Cardo, and H. L. Nakhasi. 2008. A Leishmania minicircle DNA footprint assay for sensitive detection and rapid speciation of clinical isolates. Transfusion 48: 1787-1798.
43. Rousseau, D., I. Suffia, B. Ferrua, P. Philip, Y. Le Fichoux, and J. L. Kubar. 1998. Prolonged administration of dexamethasone induces limited reactivation of visceral leishmaniasis in chronically infected BALB/c mice. Eur. Cytokine Netw. 9: 655-661.
44. Buxbaum, L. U., H. Denise, G. H. Coombs, J. Alexander, J. C. Mottram, and P. Scott. 2003. Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity. J. Immunol. 171: 3711-3717.
45. Dey, R., A. Sarkar, N. Majumder, S. Bhattacharyya Majumdar, K. Roychoudhury, S. Bhattacharyya, S. Roy, and S. Majumdar. 2005. Regulation of impaired protein kinase C signaling by chemokines in murine macrophages during visceral leishmaniasis. Infect. Immun. 73: 8334-8344.
46. Lindenstrøm, T., E. M. Agger, K. S. Korsholm, P. A. Darrah, C. Aagaard, R. A. Seder, I. Rosenkrands, and P. Andersen. 2009. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182: 8047-8055.
47. Wei, X. Q., I. G. Charles, A. Smith, J. Ure, G. J. Feng, F. P. Huang, D. Xu, W. Muller, S. Moncada, and F. Y. Liew. 1995. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375: 408-411.
48. Carvalho, E. M., R. S. Teixeira, and W. D. Johnson, Jr. 1981. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect. Immun. 33: 498-500.
49. Henao-Tamayo, M. I., D. J. Ordway, S. M. Irwin, S. Shang, C. Shanley, and I. M. Orme. 2010. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin. Vaccine Immunol. 17: 618-625.
50. Wherry, E. J., V. Teichgräber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4: 225-234.
51. Nylén, S., R. Maurya, L. Eidsmo, K. D. Manandhar, S. Sundar, and D. Sacks. 2007. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J. Exp. Med. 204: 805-817.
52. Flores-García, Y., J. L. Rosales-Encina, A. R. Satoskar, and P. Talamás-Rohana. 2011. IL-10-IFN-g double producers CD4+ T cells are induced by immunization with an amastigote stage specific derived recombinant protein of Trypanosoma cruzi. Int. J. Biol. Sci. 7: 1093-1100.
53. Bhowmick, S., T. Mazumdar, and N. Ali. 2009. Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. Infect. Immun. 77: 1514-1523.
54. Alexander, J., K. C. Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher. 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30: 2935-2943.
55. Bruhn, K. W., R. Birnbaum, J. Haskell, V. Vanchinathan, S. Greger, R. Narayan, P. L. Chang, T. A. Tran, S. M. Hickerson, S. M. Beverley, et al. 2012. Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis. Clin. Vaccine Immunol. 19: 490-498.
56. McFarlane, E., K. C. Carter, A. N. McKenzie, P. M. Kaye, F. Brombacher, and J. Alexander. 2011. Endogenous IL-13 plays a crucial role in liver granuloma maturation during Leishmania donovani infection, independent of IL-4Ra-responsive macrophages and neutrophils. J. Infect. Dis. 204: 36-43.
57. Stäger, S., J. Alexander, K. C. Carter, F. Brombacher, and P. M. Kaye. 2003. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect. Immun. 71: 4804-4807.
58. Murray, H. W., C. W. Tsai, J. Liu, and X. Ma. 2006. Visceral Leishmania donovani infection in interleukin-13-/- mice. Infect. Immun. 74: 2487-2490.
59. Coler, R. N., Y. Goto, L. Bogatzki, V. Raman, and S. G. Reed. 2007. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75: 4648-4654.
60. Goto, Y., A. Bhatia, V. S. Raman, S. E. Vidal, S. Bertholet, R. N. Coler, R. F. Howard, and S. G. Reed. 2009. Leishmania infantum sterol 24-c-methyltransferase formulated withMPL-SE induces cross-protection against L. major infection. Vaccine 27: 2884-2890.
61. Darrah, P. A., D. T. Patel, P. M. De Luca, R.W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
62. Kaveh, D. A., V. S. Bachy, R. G. Hewinson, and P. J. Hogarth. 2011. Systemic BCG immunization induces persistent lung mucosal multifunctional CD4 T(EM) cells which expand following virulent mycobacterial challenge. PLoS ONE 6: e21566.
63. Bogdan, C., H. Moll, W. Solbach, and M. Röllinghoff. 1990. Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur. J. Immunol. 20: 1131-1135.
64. Joshi, T., S. Rodriguez, V. Perovic, I. A. Cockburn, and S. Stäger. 2009. B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections. PLoS Pathog. 5: e1000431.
65. Belkaid, Y., E. Von Stebut, S. Mendez, R. Lira, E. Caler, S. Bertholet, M. C. Udey, and D. Sacks. 2002. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168: 3992-4000.
66. Stäger, S., and S. Rafati. 2012. CD8(+) T cells in leishmania infections: friends or foes? Front. Immunol. 3: 1-8.
67. Seder, R. A., and D. L. Sacks. 2004. Memory may not need reminding. Nat. Med. 10: 1045-1047.
68. Zaph, C., J. Uzonna, S. M. Beverley, and P. Scott. 2004. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10: 1104-1110.
69. Peters, N. C., N. Kimblin, N. Secundino, S. Kamhawi, P. Lawyer, and D. L. Sacks. 2009. Vector transmission of leishmania abrogates vaccine-induced protective immunity. PLoS Pathog. 5: e1000484.
70. Okwor, I., and J. Uzonna. 2008. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol. Res. 41: 123-136.
71. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150: 2322-2331.
72. Tonui, W. K., and R. G. Titus. 2007. Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/c mice. Am. J. Trop. Med. Hyg. 76: 579-584.
73. Aguilar-Be, I., R. da Silva Zardo, E. Paraguai de Souza, G. P. Borja-Cabrera, M. Rosado-Vallado, M. Mut-Martin, Mdel. R. García-Miss, C. B. Palatnik de Sousa, and E. Dumonteil. 2005. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect. Immun. 73: 812-819.
74. Rogers, M. E., O. V. Sizova, M. A. Ferguson, A. V. Nikolaev, and P. A. Bates. 2006. Synthetic glycovaccine protects against the bite of leishmania-infected sand flies. J. Infect. Dis. 194: 512-518.
75. Aslan, H., R. Dey, C. Meneses, P. Castrovinci, S. M. B. Jeronimo, G. Oliva, L. Fischer, R. C. Duncan, H. L. Nakhasi, J. G. Valenzuela, and S. Kamhawi. 2013. A new model of progressive visceral leishmaniasis in hamsters by natural transmission via bites of vector sand flies. J. Infect. Dis. DOI: 10.1093/infdis/ jis932.